Maternal alloimmunization occurs when a woman makes red blood cell antibodies after being exposed to a blood type that is different from her own. These antibodies can cross the placenta during pregnancy and target her baby’s red blood cells, a disease called hemolytic disease of the fetus and newborn (HDFN). HDFN can have devastating consequences including anemia, hyperbilirubinemia, and fetal/neonatal death. With close monitoring and timely treatment, babies with HDFN have a very high survival rate.
Whether you are newly diagnosed, navigating pregnancy, preparing for care after birth, or supporting patients, start with evidence-based, practical resources designed to help you understand what comes next at every stage.
Just Diagnosed
A brief overview of HDFN risks, monitoring, and treatment options for newly diagnosed patients and their families
Step inside the often overlooked world of maternal red blood cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN) where real families, frontline clinicians, and lifesaving research intersect.
Each episode of The Allo Podcast brings you powerful patient stories, expert perspectives, and valuable insights for providers and care teams. Whether you’re a parent navigating a high-risk pregnancy or a provider caring for alloimmunized families, we break down complex information into language you can actually use.
Our goal is to educate, empower, and equip you to advocate for the best possible care, while building community, sharing hope, and yes… having a lot of fun along the way.
Change in HDFN happens when patients share what they know, families participate in research, supporters invest in our lifesaving work, and more people understand why it matters. Come get involved with The Allo Hope Foundation and help more families find the care they need in time.